Evidence-based drug treatment of osteoporosis

  • K. K. Förster
  • K. M. Peters


Osteoporosis is a common age-related bone deterioration associated with a slow loss of cortical and trabecular bone in men and women. It usually starts in the fourth or fifth decade. Years of bone loss follow a dysbalance between bone resorption and bone formation, and cortical and trabecular bone loss accelerate in women after menopause leading to osteoporosis (Figs. 21.1 and 21.2).


Bone Mineral Density Postmenopausal Woman Vertebral Fracture Zoledronic Acid Postmenopausal Osteoporosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bartl R (2003) Management der manifesten Osteoporose — eine neue. Verantwortung für den Unfallchirurgen (Editorial). Unfallchirurg 106:525PubMedCrossRefGoogle Scholar
  2. Bartl R, Bartl C (2004) Osteoporose-Manual. Diagnostik, Prävention und Therapie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. Bischoff-Ferrari HA, Dietrich T, Orar EJ et al (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population based study of younger and older adults. Am J Med 116:634PubMedCrossRefGoogle Scholar
  4. Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293:2257PubMedCrossRefGoogle Scholar
  5. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  6. Bone HG, Greenspan SL, McKeever C et al (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85:727CrossRefGoogle Scholar
  7. Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189PubMedCrossRefGoogle Scholar
  8. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916PubMedCrossRefGoogle Scholar
  9. Chapuy MG, Arlot ME, Duboef F (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642PubMedGoogle Scholar
  10. Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241CrossRefGoogle Scholar
  11. Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, doubleb-blind, placebo controlled, parallel-group study. Arthritis Rheum 42:2309PubMedCrossRefGoogle Scholar
  12. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077PubMedCrossRefGoogle Scholar
  13. DVO-Leitlinie 2006 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause und bei Männern ab dem 60. Lebensjahr. Osteol 15:198Google Scholar
  14. Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) (2001) Bone markers: biochemical and clinical perspectives. Martin Dunitz Ltd, LondonGoogle Scholar
  15. Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Interaction Trial long-term extension. J Bone Miner Res 19:1259PubMedCrossRefGoogle Scholar
  16. Frauenfelder FW, Frauenfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348:1187CrossRefGoogle Scholar
  17. Fulton JP (1999) New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Med Health RI 82:110Google Scholar
  18. Graham DY, Malaty HM, Goodgame R (1997) Primary amino-bisphosphonates: A new class of gastrotoxic drugs comparison of alendronate and aspirin. Am J Gastroenterol 92:1322PubMedGoogle Scholar
  19. Graham DY, Malaty HM (2001) Alendronate and Naproxen are synergistic for development of gastric ulcers. Arch Intern Med 161:107PubMedCrossRefGoogle Scholar
  20. Harris ST, Eriksen EF, Davidson M et al (2001) Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890PubMedCrossRefGoogle Scholar
  21. Harris ST, Watts NB, Jackson RD et al (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557PubMedCrossRefGoogle Scholar
  22. Johnell O, Scheele WH, Lu Y et al (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985PubMedCrossRefGoogle Scholar
  23. Jones G, Nguyen T, Sambrook PN, Eisman JA (1995) Thiazide diuretics and fractures: Can meta-analysis help? J Bone Miner Res 10:106–111PubMedCrossRefGoogle Scholar
  24. Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRefGoogle Scholar
  25. Keck E, Kruse HP (1994) Osteoporose. Klinik, Diagnostik, Therapie. Fischer, Jena StuttgartGoogle Scholar
  26. LaCroix AZ, Ott SM, Ichikawa L et al (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 133:516PubMedGoogle Scholar
  27. Lane N, Leboff MS (2005) Metabolic Bone Disease. In: Harris ED, Budd RC, Firestein GS et al (eds) Kelley’s Textbook of Rheumatology, Vol. II, 7th ed. Elsevier-Saunders, Philadelphia, pp 1473–1492Google Scholar
  28. Lieberman UA, Weiss SR, Bröll HJ et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med 333:1437–1443CrossRefGoogle Scholar
  29. Lindsay R, Marcus R, Recker R (1996) Osteoporosis: What’s new in prevention and treatment Patient Care 30:24–28, 30–31, 35–36Google Scholar
  30. Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1810PubMedCrossRefGoogle Scholar
  31. MacLean C, Newbery S, Maglione M et al (2008) Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density in Osteoporosis. Ann Intern Med 148:197–213PubMedGoogle Scholar
  32. McClung M, Clemmesen B, Daifotis A et al (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial. Ann Intern Med 128:253PubMedGoogle Scholar
  33. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333PubMedCrossRefGoogle Scholar
  34. McClung MR, Wasnich RD, Hosking DJ et al (2004) Prevention of postmenopausal bone loss: Six-years results from the Early Postmenopausal Interven tion Cohort Study. J Clin Endocrinol Metab 89: 4879PubMedCrossRefGoogle Scholar
  35. Meunier PJ, Sebert JL, Reginster JY et al (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis. Osteoporosis Int 8:4CrossRefGoogle Scholar
  36. NIH (1994) Consensus Development Panel on Optimal Calcium intake JAMA 272:1942–1948CrossRefGoogle Scholar
  37. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:784–795CrossRefGoogle Scholar
  38. National Osteoporosis Foundation (2003) Physician’s guide to prevention and treatment of osteoporosis. Washington, DCGoogle Scholar
  39. Nordin BEC (1997) Calcium and osteoporosis. Nutrition 13:664–686PubMedCrossRefGoogle Scholar
  40. O’Neill S, MacLennan A, Bass S, et al. (2004) Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 33:910–919Google Scholar
  41. Peters KM (2005) Evidenz-basierte medikamentöse Behandlung der Osteoporose In: Heisel J, Drabiniok T (Hrsg) Osteoporose-Update. Med.-Lit. Verlagsges, Uelzen, S 24–30Google Scholar
  42. Reginster JY, Meurmans L, Zegels B et al (1998) The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 129:1PubMedGoogle Scholar
  43. Reid IR, Brown JP, Burckardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653PubMedCrossRefGoogle Scholar
  44. Ringe JD, Welzel D (1987) Salmon-calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33:35–39PubMedCrossRefGoogle Scholar
  45. Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly residronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141PubMedCrossRefGoogle Scholar
  46. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018PubMedCrossRefGoogle Scholar
  47. Sambrook PN, Kelly PJ, Morrison NA et al (1994) Scientific review: Genetics of osteoporosis. Br J Rheumatol 33:1007–1011PubMedCrossRefGoogle Scholar
  48. Schussheim DH, Jacobs TP, Silverberg SJ (1999) Hypocalcemia associated with alendronate (letter). Ann Intern Med 130:329PubMedGoogle Scholar
  49. Sorensen OH, Crawford GM, Mulder H et al (2003) Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experiment. Bone 32:120PubMedCrossRefGoogle Scholar
  50. Wüster C (1995) Prävention und Therapie der Osteoporose. Münch Med Wschr (MMW) 137:846–853Google Scholar

Copyright information

© Steinkopff Verlag 2008

Authors and Affiliations

  • K. K. Förster
    • 1
  • K. M. Peters
    • 2
  1. 1.Medical Consultant Osteoarthritis/OsteoporosisEngelskirchen
  2. 2.Clinic for Orthopaedic Surgery and OsteologyRhein-Sieg-KlinikNümbrecht

Personalised recommendations